Latest chemotherapy Stories
Doctors say PET scans are an effective way to determine mesothelioma prognosis and the efficacy of treatment – especially in patients who have had two round of chemotherapy. Raleigh,
Cancer types such as melanoma, prostate cancer and certain types of leukemia weaken the body by over-activating the natural immune system. Researchers have now demonstrated that selenium – naturally found in, e.g., garlic and broccoli – slows down the immune over-response.
Health Canada approves GAZYVA((TM)) (obinutuzumab), a medicine that harnesses the body's immune system to kill cancer cells, for patients with chronic lymphocytic leukemia (or CLL)
VALHALLA, N.Y., Nov.
New research indicates that as many as 47% of mesothelioma patients may not be getting the chemotherapy that could help them. Raleigh, NC (PRWEB) November 19,
Data Presented at the 19th Annual Society for Neuro-Oncology Meeting Demonstrate VAL-083 Superiority to Temozolomide in Key Preclinical Models VANCOUVER, British Columbia, MENLO PARK, Calif.,
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
- A volcanic mudflow.